Compare ABUS & NSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABUS | NSP |
|---|---|---|
| Founded | 2005 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 848.8M | 1.1B |
| IPO Year | 2008 | 1996 |
| Metric | ABUS | NSP |
|---|---|---|
| Price | $4.37 | $31.70 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $47.67 |
| AVG Volume (30 Days) | ★ 1.7M | 680.6K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 6.45% |
| EPS Growth | ★ 55.26 | N/A |
| EPS | 0.87 | ★ 0.88 |
| Revenue | $14,083,000.00 | ★ $6,812,000,000.00 |
| Revenue This Year | N/A | $3.45 |
| Revenue Next Year | $239.71 | $6.95 |
| P/E Ratio | ★ $5.10 | $35.11 |
| Revenue Growth | ★ 128.21 | 3.51 |
| 52 Week Low | $3.04 | $18.57 |
| 52 Week High | $5.10 | $65.88 |
| Indicator | ABUS | NSP |
|---|---|---|
| Relative Strength Index (RSI) | 50.92 | 53.86 |
| Support Level | $4.17 | $31.00 |
| Resistance Level | $4.60 | $33.42 |
| Average True Range (ATR) | 0.16 | 1.97 |
| MACD | 0.01 | -0.13 |
| Stochastic Oscillator | 61.46 | 69.84 |
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Insperity Inc is a company that provides a wide range of human resources and business solutions designed to help businesses improve their performance. Small and midsize enterprises are the company's primary target customers. Majority of the company's products are offered through the company's Workforce Optimization and Workforce Synchronization solutions, which comprise various human resource functions, such as payroll and employment administration, employee benefits and compensation, government compliance, performance management, training and development services, and human capital management. The company generates all of its revenue in the United States.